During the past decade, Dana-Farber/Brigham and Women's Cancer Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 19 clinical trials were completed, i.e. on average, 633.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dana-Farber/Brigham and Women's Cancer Center" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 21 trials, followed by "Radiation Therapy Oncology Group" with 6 trials sponsored, "SWOG Cancer Research Network" with 3 trials sponsored, "Brigham and Women's Hospital" with 2 trials sponsored and "BioCryst Pharmaceuticals" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana-Farber/Brigham and Women's Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 33 trials as a collaborator, "NRG Oncology" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Eastern Cooperative Oncology Group" with 2 trials as a collaborator and "SWOG Cancer Research Network" with 2 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Dana-Farber/Brigham and Women's Cancer Center" are "Leukemia" (7 trials), "Lymphoma" (6 trials), "Prostate Cancer" (5 trials), "Breast Cancer" (4 trials) and "Colorectal Cancer" (4 trials). Many other conditions were trialed in "Dana-Farber/Brigham and Women's Cancer Center" in a lesser frequency.

Most popular intervention types in "Dana-Farber/Brigham and Women's Cancer Center" are "Drug" (24 trials), "Other" (12 trials), "Biological" (9 trials), "Procedure" (9 trials) and "Radiation" (9 trials). Other intervention types were less common.

The name of intervention was led by "cisplatin" (4 trials), "rituximab" (4 trials), "cetuximab" (3 trials), "cyclophosphamide" (3 trials) and "doxorubicin hydrochloride" (3 trials). Other intervention names were less common.

The vast majority of trials in "Dana-Farber/Brigham and Women's Cancer Center" are 31 trials for "All" genders, 5 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Dana-Farber/Brigham and Women's Cancer Center". undefined are not yet recruiting, 1 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 26 completed trials in Dana-Farber/Brigham and Women's Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Dana-Farber/Brigham and Women's Cancer Center, 4 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".